Dual targeting of PD-1/PD-L1 and iL-33/ST2 signalling pathways: a promising approach in breast cancer immunotherapy

Introduction The immune checkpoint axis PD-1/PD-L1 is a cornerstone of cancer immunotherapy. However, its efficacy in breast cancer is often limited by a complex and immunosuppressive tumour microenvironment (TME). The IL-33/ST2 signalling pathway, a key player in type 2 inflammation, is increasingl...

Descripció completa

Dades bibliogràfiques

Autors principals:	Milan Jovanovic, Nevena Gajovic, Miodrag Jocic, Marina Jovanovic, Milena Jurisevic, Ivan Jovanovic
Format:	Artigo
Idioma:	Inglês
Publicat:	Taylor & Francis Group 2025-12-01
Col·lecció:	Annals of Medicine
Matèries:	Breast cancer PD-1/PD-L1 pathway IL-33/ST2 pathway immunotherapy combination therapy
Accés en línia:	https://www.tandfonline.com/doi/10.1080/07853890.2025.2593198
Etiquetes:	Afegir etiqueta Sense etiquetes, Sigues el primer a etiquetar aquest registre!